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116 - Chapter B
8.1 -  GENERAL SUMMARY
The main object ive of the research described in the present thesis was to
increase our understanding concerning the funct ional relat ionship between cel lular
sphingol ipids and the regulat ion of processes uch as cel l  di f ferent iat ion, apoptosis
and mult idrug resistance (MDR). The general  approach we employed was to
modulate the sphingol ipid metabol ism of cul tured cel ls by pharmacological-  and
biochemical means, and to study the subsequent effects of these treatments on
various cel l  physiological  phenomena.
In chapter 2 studies are described which were performed with the
glucosylceramide (GlcCer)-synthase inhibi tor D,L-threo 1-phenyl-2-decanoylamino-3-
morphol ino-1-propanol (PDMP). General ly,  the metabol ic effect of  enzyme inhibi tors
such as PDMP is not l imited to one part icular l ip id.  In a ser ies of control  experiments
however,  we were able to pinpoint he decreasing levels of GlcCer as the pr imary
cause for the observed onset of cell differentiation, whereas bioactive effects of lipids
such as ceramide (Cer)could be excluded in this respect.  Therefore, this observat ion
suggests that GlcCer is acttvely involved in the regulat ion of cel lular di f ferent iat ion
processes. On the other hand, an increase in the levels of Cer induced apoptosis
(chapter 3).  However,  this only occurred on the condit ion that Cer reached
intracel lular s i tes, s ince Cer which was generated in the outer leaf let  of  the plasma
membrane, and topological ly corresponding cel lular s i tes, fai led to induce apoptosis.
Chapter 4 descr ibes an attempt o modulate (Glc)Cer levels by y- interferon ( lFNy),  a
di f ferent iat ion-,  and apoptosis- inducing l i and. However,  in the present ly employed
HT29 model system, no such changes were observed (see discussion below). In
chapter 5 data are presented which suggest hat,  in addit ion to Cer and GlcCer, f ree
sphingoid bases might be involved in cel lular growth regulat ion, and that the
metabol ism of these l ip ids is suscept ible to pharmacological  intervent ion.
Chapter 6 descr ibes experiments which demonstrate that sphingol ipids might
be involved in the regulat ion of P-glycoprotein (Pgp)-mediated MDR, in addit ion to
their  above-described role in cel lular growth regulat ion. In l ine with these studies, we
establ ished a novel MDR cel l  l ine, i .e. ,  HT29 cel ls which specif ical ly overexpress
MRP'1 (chapter 7).  Interest ingly,  also these cel ls showed al terat ions in their
sphingol ipid composit ion, which indicates that a sphingol ipid-MDR l ink is not
restricted to Pgp-overexpressing cells.
8 .2  -  GONCLUDING DISCUSSION
The ceramide:glucosylceramide ratio; a model- Data from the literature show
that high cel lular levels of GlcCer are general ly associated with a high prol i ferat ion
act iv i ty.  ln addit ion to this,  the results descr ibed in chapter 2 indicate that a decrease
in the levels of this part icular l ip id leads to di f ferent iat ion. On the other hand, an
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Summarv and discussion - 117
increase in Cer results in the onset of the apoptotic program. In terms of cell
physiology, proliferation, differentiation and apoptosis can be considered as
increasing states of cel lular maturat ion, occurr ing on a cont inuous scale. E.g.,
concomitant with the onset of differentiation, the proliferation activity of a cell
populat ion decreases. In addit ion, apoptosis can be considered as the terminal stage
of differentiation. The present data suggest that, in the employed HT29 model
system, the state of maturat ion is determined by the levels of Cer and GlcCer. In
other words, sphingol ipid levels do not change as a consequence of a changed cel l
physiological state, but vice versa', there appears to exist a causal relation between
the levels of part icular sphingol ipids and cel lular growth. Based upon the present
observations we therefore propose a model in which the balance between Cer and
GlcCer is a determining factor for the state of cel lular maturat ion. A low Cer:GlcCer
ratio will result in a high proliferation activity of the cells. An upward shift in this ratio
wi l l  induce di f ferent iat ion of cel ls,  which thereby gradual ly lose their  prol i ferat ion
act iv i ty.  Final ly,  at  high Cer:GlcCer at ios, cel ls wi l l  i r reversibly go into apoptosis.
Future research wi l l  prove the general  val idi ty of this model.
Physiological modulation of sphingolipids and signaling - The ratio between
Cer and GlcCer is determined by the activity of GlcCer-synthase and GlcCer-
glucosidase. In addit ion, the levels of Cer are regulated by sphingomyel inases
(SMases),  ceramidases and Cer synthase. The model proposed above suggests the
involvement of signal transduction events both upstream- and downstream of these
enzymes.
In chapter 4 radiolabel ing studies are descr ibed in which we tested the
sphingol ipid-modulat ing abi l i ty of  lFNy, a known enterocyte di f ferent iat ion-,  and
apoptosis-inducing factor. However, neither short- nor long term exposure of HT29
cel ls to this cytokine had any affect on the cel lular pools of SM, Cer or GlcCer.
Simi lar results were obtained in experiments in which we employed other l igands
(TNFa, lL1, NGF), other cel l  types (HL60, U937, ol igodendrocytes, neurons) and/or
al ternat ive methods of sphingol ipid analysis (NBD-prelabel ing, measurement of
endogenous l ip id pools;  unpubl ished observat ions).  Taken together,  i t  is our
experience that reported data which suggest the presence of ligand-responsive
sphingol ipid-metabol iz ing enzymes ( i .e.  SMases),  are part icular ly di f f icul t  to
reproduce, which as such raises questions concerning the validity of these claims.
Due to this discrepancy, no experimental  data are present ly avai lable concerning
signal ing mechanisms upstream to Cer and GlcCer in HT29 cel ls.
With respect to sphingol ipid- ini t iated downstream signal ing events, abundant
literature is available on Cer (see lntroduction). However, the presently suggested
role for GlcCer in growth-related signaling is a novelty and at this moment nothing is
known concerning direct molecular targets for GlcCer and/or further downstream
signal ing events. ln future studies on GlcCer-mediated signal t ransduct ion, the
involved molecular mechanisms will therefore be a central theme.
118 - Chapter 8
Subcellular localization of bioactive sphingolipids and ABC transporfers - In
addit ion to the metabol ic aspects descr ibed above, also the subcel lular local izat ion is
a determining factor for bioactivity of sphingolipids. In this respect, an important
observat ion is descr ibed in chapter 3 in which i t  is reported that Cer only induces
apoptosis on the account that it reaches the appropriate intracellular target site
(presumably the inner leaf let  of  the plasma membrane).  In analogy to this,  and also
to other l ip id-mediated signal ing systems (e.9. the act ivat ion of protein kinase C by
diacylglycerol), it is tempting to speculate that bioactive GlcCer should also reside in
the cytoplasmic leaflet of the plasma membrane to ensure interaction with its
(hypothetical ) signaling-targets.
Like al l  other sphingol ipids however,  GlcCer is preferent ial ly present in the
outer leaf let  of  the plasma membrane. Biosynthesis of sphingol ipids mainly occurs at
the lumenal s i te of the Golgi  apparatus, which, given the vesicular transport
mechanism, topological ly corresponds with the outer leaf let  of  the plasma
membrane. With i ts s i te of synthesis at the cytoplasmic si te of the Golgi  apparatus,
which is a topological  equivalent of  the inner leaf let  of  the plasma membrane, GlcCer
biosynthesis forms a major except ion to this (see also the Introduct ion chapter).  This
suggests that,  af ter t ransport ,  at  least some GlcCer might end up at the inner leaf let .
Translocation over the membrane is conceived to be mediated by ABC-transporter
proteins (see also chapter 6),  which thus suggests a role for these proteins in the
regulat ion of the size of the rnner leaf let  GlcCer pool.  In addit ion to metabol ic
regulat ion of cel lular GlcCer levels,  i t  can thus be envisaged that GlcCer-
translocation activity plays a role in determining the state of cell differentiation. On
the other hand, data from chapter 6 strongly suggest that sphingol ipids might be
involved in the regulation of ABCtransporter protein activity.
Multidrug resistance and apoptosls - lt is now shown for the first time that a
funct ional relat ionship exists between cel lular sphingol ipid expression patterns and
the activity of the MDR protein P-glycoprotein (Pgp) In addition to Pgp
overexpression, other MDR mechanisms exist ,  one of which is the abi l i ty of  some
cel ls to escape from apoptosis.  From the present-,  and many other studies, i t  is c lear
that Cer is actively involved in the onset of this apoptotic process. Interestingly, we
made several  observat ions which indicate that (HT29) cel ls act ively avoid cel lular
accumulat ion of Cer.  For example, when cel ls were treated with the GlcCer-synthase
inhibi tor PDMP (chapter 2) or with a bacter ial  SMase (chapter 3),  Cer did not reach
the expected values. In contrast, the initial excess in Cer was actively metabolized
and the cells survived both treatments. These observations made us speculate
whether this Cer-metabolizing capacity might represent a novel apoptosis-escape
mechanism. The present data therefore suggest the existence of two functional inks
between sphingol ipid metabol ism and the MDR phenotype.
Taken together,  sphingol ipid metabol ism might provide a surtable point of
application for the development of a new type of anti-cancer drugs. A two-cutting
aspect can be envisioned since prudent ial  manipulat ion of tumor cel l  sphingol ipid
metabol ism shou
of cel l  death, bu
Obviously,  many
appl icat ions as or
Summary anddlscussion - '119
?nsporters - ln
r local izat ion is
,  an important
rr  only induces
rlar target site
r this,  and also
in kinase C by





r f  the plasma
iolgi  apparatus,
lbrane, GlcCer
n chapter).  This





'erent iat ion. On
l ipids might be
'irst time that a
n patterns and
dit ion to Pgp
abi l i ty of  some
rdies, i t  is c lear
rterestingly, we
' avoid cel lular
lcCer-synthase




funct ional l inks
itable point of
A two-cutting
r l l  sphingol ipid
metabol ism should not only provide the possibi l i ty of  growth inhibi t ion and the onset
of cell death, but also evade the often encountered obstacle of drug resistance.
Obviously, many questions will have to be elucidated, both in vitro and in vlvo, before
applications as outlined above can become reality.
